Stage‐ and histology‐specific sensitivity for the detection of lung cancer of the NELSON screening protocol—A modeling study
Open Access
- 11 July 2025
- journal article
- cancer epidemiology
- Published by Wiley in International Journal of Cancer
- Vol. 157 (11) , 2248-2258
Abstract
The Dutch–Belgian lung cancer (LC) screening trial (Nederlands–Leuvens Longkanker Screenings Onderzoek [NELSON]) demonstrated low‐dose computed tomography (CT) reduces LC mortality by 24% among men. The NELSON protocol differed from previous trials in the eligibility criteria, the use of volume‐based nodule management, and increasing screening intervals. The early‐stage sensitivity of the protocol is pivotal in determining the optimal screening strategy, such as the interval and age range. The MIcrosimulation SCreening ANalysis‐Lung natural history model was used to reproduce LC incidence and mortality by detection method (clinical or screen‐detected), sex, histology, and stage in the NELSON trial based on individual‐level data. We evaluated screening effectiveness by stage and histology, accounting for population characteristics, trial design, and LC epidemiology. We find stage IA non‐small cell LC (NSCLC) sensitivity of 24.6% (other NSCLC) to 41.0% (adenocarcinoma) at baseline screening. At repeat screening rounds, we find this increased to 70.9% for stage IA adenocarcinoma. For stage IB, the sensitivity by histology ranges from 26.4% to 77.1%; for stage II, 39.6%–81.9%. Upon detection, the probability of LC mortality prevention is estimated at 83% for stage IA. The sensitivity for detecting early‐stage LC is found to depend on the histology of cancer and is increased for adenocarcinoma at repeat screenings. Despite a low rate of referral to follow‐up screening in the NELSON trial, early‐stage CT sensitivity and the probability of mortality prevention were similar to previous estimates from the National Lung cancer Screening Trial. Previously demonstrated screening effectiveness may be maintained when implementing new programs, while reducing unnecessary follow‐up when considering NELSON evidence.Keywords
Funding Information
- ZonMw (09150161910060)
- European Commission (848294)
This publication has 41 references indexed in Scilit:
- AI integrations with lung cancer screening: Considerations in developing AI in a public health settingEuropean Journal of Cancer, 2025
- Update on Biomarkers for the Stratification of Indeterminate Pulmonary NodulesChest, 2023
- Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer ScreeningJAMA Oncology, 2021
- Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed TomographyJAMA, 2021
- Screening for Lung CancerJAMA, 2021
- Artificial intelligence and radiomics in pulmonary nodule management: current status and future applicationsClinical Radiology, 2020
- The impact of overdiagnosis on the selection of efficient lung cancer screening strategiesInternational Journal of Cancer, 2017
- Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trialsCancer, 2014
- The National Lung Screening Trial: Results stratified by demographics, smoking history, and lung cancer histologyCancer, 2013
- Analysis of lung cancer incidence in the nurses’ health and the health professionals’ follow-up studies using a multistage carcinogenesis modelCancer Causes & Control, 2007